Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alx Oncology Holdings Inc (NQ: ALXO )

1.520 +0.070 (+4.83%)
Streaming Delayed Price Updated: 11:44 AM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alx Oncology Holdings Inc

< Previous 1 2 3 4 5 Next >
AMC Preferred Equity Units, Accolade And Some Other Big Stocks Moving Higher On Friday
U.S. stocks traded mixed, with the Dow Jones gaining over 50 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia
From ALX Oncology
Via GlobeNewswire
ALX Oncology Appoints Scott Garland to its Board of Directors
From ALX Oncology
Via GlobeNewswire
ALX Oncology's Evorpacept Gets Orphan Drug Tag For Gastric Cancer
The  
Via Benzinga
ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Present New Clinical Data on Evorpacept in Acute Myeloid Leukemia at 64th ASH Annual Meeting
From ALX Oncology
Via GlobeNewswire
ALX Oncology Announces Upcoming Investor Conference Participation
From ALX Oncology
Via GlobeNewswire
ALX Oncology Enters $100 Million Loan Facility Agreement with Oxford Finance and Silicon Valley Bank to Support Ongoing Development of Evorpacept
Expects to extend cash runway to mid-2025 
From ALX Oncology
Via GlobeNewswire
ALX Oncology Announces Trials in Progress Abstracts Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
From ALX Oncology
Via GlobeNewswire
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
ALX Oncology Shares Climb As Mid-Stage Triple Combination Colorectal Cancer Study Kicks-off
ALX Oncology Holdings (NASDAQ: ALXO) has initiated a Phase 2 investigator-sponsored study of evorpacept in combination with Eli Lilly’s (NYSE: LLY) ERBITUX (cetuximab) and Merck’s (NASDAQ: 
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
ALX Oncology Shares Gain As FDA Grants Fast Track Status To Head And Neck Cancer Candidate
ALX Oncology Holdings (NASDAQ: ALXO) receives Fast Track designation from the U.S. Food and Drug Administration (FDA) for its lead asset Evorpacept in combination with KEYTRUDA (pembrolizumab) for the... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Guardant Health (NASDAQ:GH) stock rose 14.8% to $55.23 during Tuesday's after-market session. The market value of their outstanding shares is at $5.6 billion. 
Via Benzinga
The Daily Biotech Pulse: Eli Lilly Modifies COVID-19 Treatment Pact, Oyster Point Outlines Restructuring Plan, Icosavax Posts Interim RSV Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
ALX Oncology Shares Soar As FDA Grants Orphan Drug Status To Blood Cancer Candidate
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ALX Oncology Holdings’ (NASDAQ: ALXO) Evorpacept for the treatment of patients with acute myeloid leukemia (AML). 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Monday's session saw 84 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 36 companies achieved new lows for the year. 
Via Benzinga
ALX Oncology Holdings: Q4 Earnings Insights
ALX Oncology Holdings (NASDAQ:ALXO) reported its Q4 earnings results on Monday, February 28, 2022 at 07:00 AM. Here's what investors need to know about the announcement... 
Via Benzinga
The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's morning session, 34 stocks hit new 52-week lows. Things to Consider About Today's 52-Week Lows: Illumina (NASDAQ:ILMN) was the biggest company... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Vaccinex (NASDAQ:VCNX) shares moved upwards by 30.4% to $1.33 during Wednesday's pre-market session. The market value of their outstanding shares is at $40.9... 
Via Benzinga
Gastrointestinal Cancer Treatment Trials Driven by Rising Incidences of Colorectal Cancer
Palm Beach, FL – January 20, 2022 – FinancialNewsMedia.com News Commentary – Despite significant progress in the treatment of gastric cancer, it is still among the leading causes of deaths due to... 
Via FinancialNewsMedia
Topics Death
Exposures Death
Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2021
Upgrades According to Loop Capital, the prior rating for Williams-Sonoma Inc (NYSE: 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Barclays lifted the price target on FactSet Research Systems Inc. (NYSE: 
Via Benzinga
ALX Oncology's Evorpacept Data Fails To Impress At ASH Presentation
ALX Oncology Holdings Inc (NASDAQ: ALXO) presented initial clinical data from its ongoing Phase 1 / 2 trial evaluating evorpacept combined with azacitidine for... 
Via Benzinga
58 Biggest Movers From Yesterday
Gainers Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares jumped 80.4% to close at $90.08 on Monday. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-... 
Via Benzinga
40 Stocks Moving In Monday's Mid-Day Session
Gainers Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares climbed 83.4% to $91.52. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-cash transaction.... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.